American Biotech company Moderna Inc’s vaccine for coronavirus ‘mRNA-1273’ has shown positive results in its early human trials. The vaccine showed positive clinical data against the virus in its phase 1 study of its trails.
The company announced on Monday that the vaccine’s initial trials on patients have been “generally safe and well-tolerated”. The company also added that increases in immunogenicity dependent dose were seen across the three dose levels.
Phase 2 study of the vaccine is expected to start soon. The third phase study of the vaccine will start in July. mRNA-1273 provided full protection against viral replication in the lungs in a mouse challenge model.